Excelya
Excelya is recorded as a service provider in 74 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 20 of 74 trials · Latest update first
Double-blind, randomised, placebo-controlled, phase IIa trial on the efficacy and tolerability of an 8-week treatment with two different doses of budesonide orodispersible tablets vs. placebo for prevention of oesophageal strictures in adult patients after endoscopic submucosal dissection
Sponsor Dr. Falk Pharma GmbH
- Start (EU)
- Latest update
- Estimated end
A Phase 2 Randomized, Double-blind, Placebo‑controlled, Dose‑ranging Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Subjects With Type 2 Diabetes Mellitus
Sponsor Amgen Inc.
- Start (EU)
- Latest update
- Estimated end
A Randomized, Open-Label, Controlled Phase 3 Study Comparing Daratumumab, Lenalidomide and Dexamethasone Induction followed by Linvoseltamab Versus continued Daratumumab, Lenalidomide, and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma Patients
Sponsor European Myeloma Network B.V.
- Start (EU)
- Latest update
- Estimated end
A Phase 2b Randomized, Double-blind, Active- and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Induction and Maintenance Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Severely Active Crohn’s Disease
Sponsor Janssen - Cilag International
- Start (EU)
- Latest update
- Estimated end
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
Sponsor UCB Biopharma
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Open-Label, Multicenter, Randomized Study of Subcutaneous vs Intravenous Tarlatamab in Participants with Relapsed Extensive-Stage Small Cell Lung Cancer After Platinum-based First-line chemotherapy (DeLLphi-315)
Sponsor Amgen Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase III, Open-label, Sponsor-blind, Randomized Study of Dato-DXd With or Without Osimertinib Versus Platinum-based Doublet Chemotherapy for Participants with EGFR-mutated Locally Advanced or Metastatic Non-small Cell Lung Cancer whose Disease has Progressed on Prior Osimertinib Treatment (TROPION-Lung15)
Sponsor AstraZeneca AB
- Start (EU)
- Latest update
- Estimated end
A prospective, open-label, single-arm, multicenter pharmacokinetic study evaluating the placental transfer of dapirolizumab pegol to the infant(s) from pregnant study participants with active systemic lupus erythematosus who are administered dapirolizumab pegol
Sponsor UCB Biopharma
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Multicenter, Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of Dapirolizumab Pegol Treatment in Study Participants With Systemic Lupus Erythematosus
Sponsor UCB Biopharma
- Start (EU)
- Latest update
- Estimated end
A Phase 1/2, Multicenter, Open-label, Study to Determine the Recommended Dose and Regimen, and Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination with Standard Treatments in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
Sponsor Celgene Corp.
- Start (EU)
- Latest update
- Estimated end
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impactof Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and Overweight or Obesity (MARITIME-CV)
Sponsor Amgen Inc.
- Start (EU)
- Latest update
- Estimated end
Open-label, Uncontrolled, Multicenter Trial to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Inebilizumab in Children From 2 Years to Less Than 18 Years of Age with Immunoglobulin G4 related Disease (IgG4-RD)
Sponsor Not reported
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, 52-week, Placebo-controlled, Double-blind Study With Rerandomization to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab (AMG 451) in Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASTRO)
Sponsor Amgen Inc.
- Start (EU)
- Latest update
- Estimated end
Operational learnings available8 trial-level findings · Read insights
- The protocol specified that both co-primary endpoints had to achieve statistical significance to declare trial success.
- Participants achieving vIGA-AD 0/1 and/or EASI-75 at Week 24 without atopic-dermatitis rescue therapy continued into blinded maintenance with re-randomization to every-4-week or every-8-week dosing.
- Eligibility was updated to require at least 12 months of atopic dermatitis before consent and an EASI score of at least 16 at initial screening.
- Participants previously treated systemically for atopic dermatitis could be eligible after an appropriate washout because they were considered inadequate responders to topical treatments.
- Tuberculosis eligibility was clarified to allow a positive or indeterminate QuantiFERON test after adequate completed prophylaxis, absent tuberculosis symptoms, new exposure, or radiographic evidence of active disease.
- The protocol added cardiovascular exclusions, including New York Heart Association class III/IV heart failure, uncontrolled hypertension, inadequately treated cardiovascular conditions, and recent cardiovascular events.
- Rescue-therapy rules were updated to require temporary interruption or permanent discontinuation of investigational product according to systemic corticosteroid duration and use of specified systemic therapies or topical JAK inhibitors.
- Patient-reported outcome assessments using DLQI/CDLQI were clarified for participants aged 12 years or older and those younger than 12 years.
These findings describe the trial, not the service provider’s performance or responsibility.
A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression (FORTITUDE-102)
Sponsor Amgen Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2/3, Randomized, Double-blind, Multicenter, Placebo-Controlled Study Of Inebilizumab In Participants With Autoimmune Hepatitis
Sponsor Amgen Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein (a)
Sponsor Amgen Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2b Randomized, Double-blind, Active- and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Induction and Maintenance Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Severely Active Ulcerative Colitis
Sponsor Janssen - Cilag International
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Apremilast in Children From 5 to Less Than 18 Years of Age With Active Juvenile Psoriatic Arthritis (PEAPOD)
Sponsor Amgen Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
Sponsor Amgen Inc.
- Start (EU)
- Latest update
- Estimated end
C3601008 - A PHASE 2A MULTICENTER, OBSERVER-BLINDED, RANDOMIZED 2 ARM STUDY TO INVESTIGATE PHARMACOKINETICS, SAFETY, TOLERABILITY AND EFFICACY OF INTRAVENOUS AZTREONAM-AVIBACTAM ± METRONIDAZOLE COMPARED TO BEST AVAILABLE THERAPY (BAT) IN PEDIATRIC PARTICIPANTS 9 MONTHS TO LESS THAN 18 YEARS OF AGE WITH SERIOUS GRAM-NEGATIVE BACTERIAL INFECTIONS INCLUDING COMPLICATED INTRA-ABDOMINAL INFECTION
Sponsor Pfizer Inc.
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Excelya?
The 2026-10-09 snapshot links Excelya to 74 distinct CTIS trials. Recorded services include Clinical monitoring, Regulatory services, Investigator recruitment, Project management, among 39 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Excelya?
The most frequently recorded therapeutic areas are Immunology, Solid Tumor Oncology, Dermatology, Gastroenterology. Recorded phases include Phase 3, Phase 2, Phase 1. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Excelya conducted?
The linked trials record locations in 27 countries, including Greece, Spain, Italy, France, Germany. These are trial locations, not confirmed office locations or countries where Excelya delivered services.
What can this page tell me about Excelya's trial experience?
Browse 74 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 3 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 6 recorded name variants under Excelya. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Excelya
- Excelya Belgium
- Excelya France
- Excelya Germany GmbH
- Excelya Greece CRO Single Member S.A.
- Excelya Poland Sp. z o.o.